KURA · Kura Oncology, Inc.
$10.86
+0.77 (+7.63%)
At close · Aug 14
Market Cap
$966.11M
Shares
88.96M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Troy Wilson | Ph.D., J.D. President and Chief Executive Officer | $4,735,016 |
| Brian Powl | Chief Commercial Officer | $2,669,238 |
| Kathleen Ford | Chief Operating Officer | $1,902,487 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Troy Wilson | Ph.D., J.D. President and Chief Executive Officer | $6,239,098 |
| Stephen Dale | Former Chief Medical Officer | $2,508,675 |
| Kathleen Ford | Chief Operating Officer | $2,501,838 |
| Teresa Bair | Chief Legal Officer and Secretary | $2,271,872 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Troy Wilson | Ph.D., J.D. President and Chief Executive Officer | $5,251,407 |
| Stephen Dale | Former Chief Medical Officer | $2,465,473 |
| Kathleen Ford | Chief Operating Officer | $2,157,853 |
| Teresa Bair | Chief Legal Officer and Secretary | $1,982,334 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Troy Wilson | Ph.D., J.D. President and Chief Executive Officer | $5,304,349 |
| Stephen Dale | Former Chief Medical Officer | $3,443,477 |
| Kathleen Ford | Chief Operating Officer | $2,529,697 |
| Kirsten Flowers | Former Chief Commercial and Corporate Strategy Officer | $2,500,538 |
| Marc Grasso | Former Chief Financial Officer and Chief Business Officer | $1,694,717 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Troy Wilson | Ph.D., J.D. President and Chief Executive Officer | $8,743,784 |
| Marc Grasso | Former Chief Financial Officer and Chief Business Officer | $4,356,608 |
| Kathleen Ford | Chief Operating Officer | $3,653,257 |
| Kirsten Flowers | Former Chief Commercial and Corporate Strategy Officer | $3,289,353 |
| Stephen Dale | Chief Medical Officer | $2,928,682 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Troy Wilson | Ph.D., J.D. President and Chief Executive Officer | $4,192,116 |
| Stephen Dale | Chief Medical Officer | $3,286,154 |
| Kirsten Flowers | Former Chief Commercial and Corporate Strategy Officer | $2,948,392 |
| Bridget Martell | M.A., M.D.^(^^14)^ Former Acting Chief Medical Officer | $2,431,646 |
| Marc Grasso | Former Chief Financial Officer and Chief Business Officer | $1,589,108 |
| Kathleen Ford | Chief Operating Officer | $1,038,161 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Kathleen Ford | Chief Operating Officer | $3,485,030 |
| Troy Wilson | Ph.D., J.D. President and Chief Executive Officer | $3,236,217 |
| John Farnam | Former Chief Operating Officer | $2,163,376 |
| Marc Grasso | Former Chief Financial Officer and Chief Business Officer | $2,112,282 |
| Antonio Gualberto | M.D., Ph.D. Former Head of Development and Chief Medical Officer | $2,050,193 |
| James Basta | Chief Legal Officer and Secretary | $1,933,832 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Troy Wilson | Ph.D., J.D. President and Chief Executive Officer | $4,745,838 |
| Marc Grasso | M.D.^(^^4)^ Chief Financial Officer and Chief Business Officer | $3,634,267 |
| Antonio Gualberto | M.D., Ph.D. Former Head of Development and Chief Medical Officer | $2,021,923 |
| John Farnam | Former Chief Operating Officer | $1,717,340 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Troy Wilson | Ph.D., J.D. President and Chief Executive Officer | $1,721,112 |
| Antonio Gualberto | M.D., Ph.D. Former Head of Development and Chief Medical Officer | $1,258,058 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael J. Vasconcelles, M.D. | Class III director | Appointed | 2026-06-04 |
| Mary T. Szela | Class III director | Appointed | 2026-06-04 |
| Diane Parks | Class III director | Appointed | 2026-06-04 |
| Carol Schafer | Class II director | Appointed | 2025-06-06 |
| Thomas Malley | Class II director | Appointed | 2025-06-06 |
| Helen Collins, M.D. | Class II director | Appointed | 2025-06-06 |
| Francis Burrows, Ph.D. | Chief Scientific Officer | Appointed | 2025-01-06 |
| Mollie Leoni, M.D. | Chief Medical Officer | Appointed | 2025-01-06 |
| Stephen Dale, M.D. | Chief Medical Officer | Resigned | 2025-01-06 |
| Michael J. Vasconcelles, M.D. | Class III director of the Company | Appointed | 2024-09-17 |
| Faheem Hasnain | Class I director | Appointed | 2024-06-07 |
| Troy E. Wilson, Ph.D., J.D. | Class I director | Appointed | 2024-06-07 |
| Mary T. Szela | Class III director | Appointed | 2023-06-02 |
| Diane Parks | Class III director | Appointed | 2023-06-02 |
| Kirsten Flowers | Chief Commercial Officer | Resigned | 2023-01-13 |
| Troy E. Wilson, Ph.D., J.D. | principal financial officer | Appointed | 2022-02-01 |
| Thomas Doyle | principal accounting officer | Appointed | 2022-02-01 |
| Marc Grasso, M.D. | principal accounting officer | Resigned | 2022-02-01 |
| Thomas Doyle | Senior Vice President, Finance and Accounting | Appointed | 2022-02-01 |
| Marc Grasso, M.D. | Chief Business Officer | Resigned | 2022-02-01 |
| Marc Grasso, M.D. | Chief Financial Officer | Resigned | 2022-02-01 |
Key facts
CIK
1422143
CUSIP
50127T109
13F (30d)
211 filings
203 filers
Visit website
Investor relations